UK Sector Leaders Launch Medical Radionuclide Taskforce

These materials are vital for the diagnosis and treatment of cancer, with more than 700,000 NHS patients relying on them every year. Despite this critical need, the UK remains vulnerable, importing approximately 90% of its supply from overseas.

The formation of the MRNT follows a leadership summit held during Nuclear Week in Parliament early in the year. It has been established to provide a single, authoritative voice for a sector currently fragmented across multiple government departments. The Taskforce brings together members from across the NHS, industry, and academia to ensure that nuclear medicine becomes a central pillar of the UK’s Industrial Strategy.

A spokesperson for the MRNT said:

“The UK has a pioneering history in nuclear medicine, but ‘potential’ only matters if it can be delivered to the frontline. We have seen the impact when manufacturing shutdowns abroad lead to people missing essential treatments; it is a punch in the gut that underscores why we must move as fast as possible to accelerate domestic production. By building sovereign capability, we can ensure that no patient in this country has their treatment delayed by a supply chain that starts elsewhere.”

The Taskforce’s primary objective is the delivery of a Strategic Roadmap & Sector Report. This roadmap will provide actionable recommendations directly to the Government to address critical supply vulnerabilities and define a resilient national strategy for domestic production. This work includes shaping the future of UK isotope supply, engaging with Parliament and government departments such as DHSC and DESNZ, and DSIT, and hosting technical roundtables to resolve the logistical and manufacturing barriers to domestic production.

By decentralising production and building sovereign capability, the MRNT aims to ensure that the UK is no longer vulnerable to border delays or international manufacturing failures.